The Department of Science and Technology (DOST)-funded clinical trials on lagundi as an adjunct therapy for COVID-19, conducted by University of the Philippines Manila researchers, have successfully shown the herbal medicine’s symptomatic relief benefit to mild coronavirus cases.
Rowena Cristina Guevara, DOST undersecretary for research and development, said that the UP Manila clinical trial team led by Dr. Cecilia Nelia Maramba-Lazarte finished its study which showed that lagundi tablets administered to mild COVID-19 cases without comorbidities had relieved the various symptoms of patients.
“That’s their conclusion, that it brought symptomatic relief to the mild cases of the disease especially those with no taste and smell,” Guevara told The STAR in a phone interview over the weekend.
